AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: Single dose of matching placebo; soft capsules for oral use.
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Multiple doses of matching placebo; soft capsules for oral use.
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-ACT-1014-6470 microtracer
Description: Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
Study NCT04183686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-ACT-1014-6470 microtracer placebo
Description: Single dose of matching placebo; soft capsules for oral use.
Study NCT03868501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back task
Description: All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
Study NCT02169596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Blood tests taken for flow cytometry
Study NCT02169596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EndoPAT - endothelial assessment
Study NCT03231553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MiQuit text message support programme
Description: MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
Study NCT01155050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-health Home Monitoring
Description: Daily tele-health monitoring data will be collected from randomized participants.
Study NCT01155050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TrestleTree Telephone Coaching
Description: Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
Study NCT02439281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
Study NCT01984541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artemisia vulgaris
Description: Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study NCT03253991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
Study NCT00362063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone (Nutropin)
Description: growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
Study NCT01155050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-health Home Monitoring Plus Trestle Telephone Coaching
Description: Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
Study NCT02318875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo adminstration
Description: 1 placebo capsule per day during 12 weeks; oral ingestion
Study NCT01405235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
Study NCT01405235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Paclitaxel
Description: Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
Study NCT03773861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: errors made in one BLS session
Description: BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
Study NCT03360422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
Study NCT02449473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Subcutaneous Injection
Study NCT02449473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT02491996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: desire satisfaction-targeted intervention for disordered gamblers
Description: This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
Study NCT04227041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib in combination with capecitabine
Description: Pyrotinib in combination with capecitabine
Study NCT01919541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prehabilitation
Description: All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
Study NCT01919541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hyperinsulinemic euglycemic isoaminoacid clamp
Description: A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
Study NCT01919541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hyperinsulinemic euglycemic hyperaminoacid clamp
Study NCT01919541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey protein supplementation
Study NCT01919541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prehabilitation
Description: All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
Study NCT00706719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Androxal
Description: 25 mg Androxal capsules, 1 capsule daily for 6 months
Study NCT03360422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focus Group
Description: After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
Study NCT03360422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usability study
Description: After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
Study NCT01662180 — intervention group
Intervention type: DRUG
Intervention: Follicle Stimulating Hormone
Description: All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
Study NCT02954848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets
Study NCT02954848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-438 placebo-matching tablets
Study NCT02954848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 10 mg
Description: TAK-438 tablets
Study NCT02206386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MHTraining-Net
Description: See Arm Description for more details.
Study NCT02206386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Support
Description: Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
Study NCT01835899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to BI 1015550
Study NCT01835899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: medium dose 1 powder for oral solution
Study NCT01835899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: medium dose 2 powder for oral solution
Study NCT04785209 — intervention group
Intervention type: OTHER
Intervention: Mean platelet volume, lymphocyte number, STEMI clinical risk scores
Description: Lab parameters
Study NCT03278561 — intervention group
Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Sputum induction according to the ERS protocol
Study NCT03278561 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: A blood sample of 100ml will be taken.
Study NCT05059275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified ostium obstruction surgery
Description: An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
Study NCT00284128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE7688
Description: oral administration (capsules)
Study NCT01835899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1015550
Description: low dose 2 powder for oral solution
Study NCT01835899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: low dose 1 powder for oral solution
Study NCT03651713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLU+EX
Description: Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
Study NCT03651713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLU
Description: Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
Study NCT02012543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar jelly
Study NCT00706719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim 1%
Description: Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
Study NCT00284128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan-potassium
Description: oral administration (capsules)
Study NCT01224314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing potassium concentration in dialysis fluids
Description: The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
Study NCT02488161 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02346552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap
Study NCT04549857 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy
Description: The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment.
Study NCT04549857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment.
Study NCT02010710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFANT software
Description: The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
Study NCT00785928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Study NCT03551067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine mixed with juice was given to the child orally preoperatively.
Study NCT03551067 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam/Ketamine
Description: Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
Study NCT03765931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Study NCT04458831 — intervention group
Intervention type: DRUG
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT03765931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Study NCT03765931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Study NCT04458831 — intervention group
Intervention type: DRUG
Intervention: Pomalidomide
Description: Pharmaceutical form: oral
Study NCT04458831 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Pharmaceutical form: oral
Study NCT04458831 — intervention group
Intervention type: DRUG
Intervention: Carfilzomib
Description: Pharmaceutical form: solution for infusion
Study NCT03931551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]
Description: Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
Study NCT02551783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethroplasty with buccal mucosa graft
Description: A surgery to correct urethral stricture
Study NCT02551783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral Buccal
Description: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
Study NCT03528733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Energy Digital Radiography Detector System
Description: A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
Study NCT04617860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
Study NCT04189614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cofetuzumab Pelidotin
Description: Intravenous (IV) infusion
Study NCT04687930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve block
Description: nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
Study NCT04687930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intra-articular steroid injection
Description: Triamcinilone injection into the knee joint under ultrasound guidance.
Study NCT01762540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 37.5 mg x1 for 5 days
Study NCT01762540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Placebo
Study NCT02670291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro Cool-B65A/P, Magventure
Description: combined active and sham coil
Study NCT02670291 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro Cool-B65A/P, Magventure
Description: combined active and sham coil
Study NCT00478257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bright white light
Description: Intervention: Bright white light administered for 30 minutes each morning
Study NCT00478257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparator red light treatment
Description: dim red light administered for 30 minutes every morning